Open an account

Abcellera Biologics

ABCL · NASDAQ

$11.71−$0.22 (−1.84%)TodayMarket closed ·
Prev close $11.93

About ABCL

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Employees
562
Headquarters
Vancouver, British Columbia
Listed
Dec 11, 2020
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
abcellera.com

ABCL key statistics

Market cap
3.79B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.17M
Volume
4.26M
Open price
$11.65
High today
$11.95
Low today
$11.41
52 Week high
$15.02
52 Week low
$2.75

Abcellera Biologics (ABCL) at a glance

As of Oct 20, 2026, Abcellera Biologics (ABCL) shares are priced at $11.71, giving the company a market cap of 3.79B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.41 and $11.95. The current price is 2.6% above the day's low and 2.0% below its high.

Volume so far is 4.26M shares, in line with the average of 5.17M shares a day.

Over the past year Abcellera Biologics has ranged from $2.75 to $15.02, and now sits 73% of the way up that range.

Abcellera Biologics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.1457.

The average analyst price target is $17.00, 45.2% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

78%of 9 analyst ratings say Buy
  • Buy77.8%
  • Hold22.2%
  • Sell0.0%
Price target · 12 analystsAvg $17.00
Low
$9.09
Now
$11.71
High
$31.50

ABCL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 43.0% on average.

  1. Q3 FY24: reported -$0.17 per share against an estimate of -$0.1547
  2. Q4 FY24: reported -$0.11 per share against an estimate of -$0.1568
  3. Q1 FY25: reported -$0.15 per share against an estimate of -$0.1448
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.1693
  5. Q3 FY25: reported -$0.19 per share against an estimate of -$0.1721
  6. Q4 FY25: reported -$0.03 per share against an estimate of -$0.1775
  7. Q1 FY26: reported -$0.14 per share against an estimate of -$0.1996
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.1457

ABCL news

  • Press releaseBusiness Wire

    AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

  • Press releaseBusiness Wire

    AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

  • Press releasePRNewswire

    AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

  • Press releaseBusiness Wire

    AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

  • Vandana Singh

    What'sGoing On With AbCellera Biologics Stock On Tuesday?

  • Press releaseGlobe Newswire

    Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

  • Press releaseBusiness Wire

    AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

  • Vandana Singh

    What's Going on With AbCellera Biologics Stock On Wednesday?

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.